0800 Immune

0800 466 863

Changes to the National Immunisation Schedule

The full PHARMAC notification of changes to the National Immunisation Schedule is available on the PHARMAC website www.pharmac.govt.nz under News/Notifications. The following details have been taken directly from page one of the
PHARMAC notification:

From 1 January 2017

Human papillomavirus (HPV) vaccine

  • Funded access will be widened to include people up to the age of 26 years.
  • A two-dose regimen will be funded for those children aged 14 years and under.
    • The two-dose regimen was recently approved by Medsafe.
  • A three-dose schedule will be funded for people aged 15-26 years inclusive.
  • The 4 valent (Gardasil) HPV vaccine will be replaced with the 9 valent (Gardasil 9) vaccine.
  • Females who have started a three-dose regimen of 4 valent Gardasil will be able to complete their remaining doses in 2017.

From 1 July 2017

Varicella vaccine

  • Funded access of the varicella vaccine (Varilrix) will be widened to include one dose for primary vaccination in children at 15 months old and a catch up in general practice of one dose for previously unvaccinated children at 11 years old, who have not previously had a varicella infection (chickenpox).
  • Funding criteria for high risk patients will remain unchanged.
  • There will be a change in pack size from 1 to 10 injections per pack.

Pneumococcal conjugated vaccine (PCV)

  • The 13 valent (Prevenar 13) PCV13 pneumococcal vaccine will be replaced by the 10 valent (Synflorix) PCV10 vaccine on the National Immunisation Schedule.
  • Prevenar 13 will remain available for high risk patients only.

Rotavirus vaccine

  • The currently listed RotaTeq brand will be replaced by the Rotarix brand.
  • The current three-dose regimen will be replaced with a two-dose regimen.

Measles, mumps and rubella vaccine

  • The currently listed MMR-II brand will be replaced by the Priorix brand.

Haemophilus influenzae type b (Hib) vaccine

  • The currently listed Act-HIB brand will be replaced by the Hiberix brand.

No changes to the following listed vaccines

  • Diphtheria, tetanus and acellular pertussis vaccine (Boostrix);
  • Diphtheria, tetanus, acellular pertussis and polio vaccine (Infanrix IPV);
  • Diphtheria, tetanus, pertussis, polio, haemophilus influenzae type b and hepatitis B vaccine (Infanrix Hexa); and
  • Adult diphtheria and tetanus vaccine (ADT Booster).

Last updated: Feb 2017